A California biopharmaceutical company that makes Afrezza, an inhaled insulin for people with type 1 and type 2 diabetes. Instead of a needle, patients breathe a dry-powder insulin through a small inhaler, with the powder absorbed quickly through the lungs to manage mealtime blood sugar. Founder Alfred E. Mann, a serial inventor of medical devices, named the firm after himself and shaped it in the early 2000s by merging several of his companies. A fun quirk: Mann's dream was to free people with diabetes from daily injections — a needle-free ambition baked into the company's very name.
Marasco DominicPres, Endocrine Business Unit · 1 transaction
+10.5%
344.2K
8.5K
—
—
Prentiss Christopher BChief Financial Officer · 2 transactions
-1.4%
338.9K
5.0K
—
—
Hooper Anthony CDirector · 1 transaction
+17.4%
236.2K
35.0K
—
—
Consiglio Ronald JDirector · 1 transaction
-75.8%
132.3K
10.0K
—
—
Shannon James SamuelDirector · 1 transaction
-67.9%
36.5K
12.0K
—
—
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -20.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.